Login
The Trump administration has opened a deeper health review of glyphosate, the world’s most widely used herbicide, through a new U.S. Department of Health and Human Services (HHS)-U.S. Environmental Protection Agency (EPA) partnership.
U.S. Health Secretary Robert F. Kennedy (RFK) Jr. says government should “follow the evidence wherever it leads,” while EPA Administrator Lee Zeldin promises a transparent reassessment of cancer, reproductive, developmental and other potential effects.
Yet the move creates an unusual policy tension: Just seven months earlier, President Donald Trump invoked the Defense Production Act to protect domestic production of glyphosate-based herbicides, calling them crucial to agricultural productivity and national security.
As the midterms approach, is the Trump administration giving RFK Jr. more latitude to publicly champion medical-freedom issues that previously appeared more constrained?
Science meets industrial policy
The Sept. 22 memorandum creates a joint technical group drawing on the National Institute of Environmental Health Sciences, National Toxicology Program, National Cancer Institute, Centers for Disease Control and Prevention, U.S. Food and Drug Administration and other agencies.
Importantly, this is not simply another cancer review. Officials say they will examine glyphosate formulations and surfactants, occupational exposure, dietary exposure — including preharvest applications — biomonitoring, genotoxicity, reproductive and developmental effects, and emerging questions involving the gut microbiome.
EPA expects an updated human-health assessment around late 2026 to early 2027.
That breadth is a strength. “Glyphosate” and commercial glyphosate formulations are not necessarily identical toxicological questions.
A contradiction? Not quite — but watch the collision
In February, Trump’s executive order, as reported by TrialSite News, described glyphosate-based herbicides as a “cornerstone” of American agricultural productivity and directed the U.S. Department of Agriculture secretary to ensure continued supply.
Most strikingly, the order instructed officials implementing it not to place the corporate viability of any domestic glyphosate producer at risk.
That creates tension, but not necessarily contradiction. The February order concerns supply and national security; EPA retains separate statutory responsibility to determine whether glyphosate satisfies federal safety requirements.
The real test comes if those objectives collide.
Suppose HHS-supported research identifies a significant health risk requiring tighter exposure limits. Would EPA impose restrictions even if they materially threaten the domestic producer Washington has simultaneously pledged to protect?
That is where “follow the science” becomes more than a slogan.
TrialSite has previously scrutinized the Trump administration’s broader reliance on executive authority and the potential collision between policy objectives and independent regulatory decision-making. Glyphosate now provides a particularly concrete test.
Neither ‘safe’ nor ‘poison’ is good enough
EPA historically concluded glyphosate was “not likely to be carcinogenic to humans,” but the U.S. Court of Appeals for the 9th Circuit vacated the human-health portion of EPA’s 2020 interim decision in 2022, sending the agency back to reconsider its work.
EPA is now systematically reviewing newer literature published since its previous search.
The administration deserves credit for reopening unresolved scientific questions rather than treating prior conclusions as immutable.
But transparency requires more than publishing a memorandum. EPA should disclose which studies survive its quality filters, why others are excluded, how formulation toxicity differs from glyphosate alone and whether economic or national-security considerations influence health-protection decisions.
The hardest question is wonderfully simple: If the new science conflicts with February’s industrial policy, which one wins?
Originally published by TrialSite News.
